Recommended adjuvant therapy for early-stage ovarian cancer depends
on tumor sub-stage and grade. Two randomized controlled trials
by the Gynecologic Oncology Group (GOG) demonstrated that adjuvant
chemotherapy did not provide a survival benefit in patients with lowrisk
tumors